Shenzhen YHLO Biotech Co., Ltd. (SHA:688575)
China · Delayed Price · Currency is CNY 10.12
+0.52 (5.42%)
Aug 14, 2026, 3:00 PM CST
Shenzhen YHLO Biotech Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 5,782 | 8,114 | 9,010 | 12,993 | 11,142 | 13,993 | |
Market Cap Growth | -36.04% | -9.95% | -30.65% | 16.62% | -20.38% | - |
Enterprise Value | 6,050 | 8,403 | 9,226 | 12,949 | 10,739 | 13,697 |
Last Close Price | 10.12 | 14.17 | 15.54 | 22.21 | 18.64 | 23.10 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 197.00 | 347.62 | 29.88 | 36.60 | 11.01 | 68.34 |
Forward PE | 29.33 | 21.63 | 16.84 | 27.31 | 17.99 | 34.64 |
PS Ratio | 3.23 | 4.48 | 4.48 | 6.33 | 2.80 | 11.88 |
PB Ratio | 2.14 | 3.02 | 3.34 | 5.13 | 4.56 | 9.24 |
P/TBV Ratio | 2.27 | 3.21 | 3.51 | 5.49 | 5.06 | 9.84 |
P/FCF Ratio | 61.13 | 129.60 | - | - | 10.95 | - |
P/OCF Ratio | 11.43 | 19.23 | 17.00 | - | 7.04 | 53.90 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.38 | 4.64 | 4.59 | 6.31 | 2.70 | 11.63 |
EV/EBITDA Ratio | 12.72 | 17.74 | 15.97 | 29.37 | 8.32 | 44.16 |
EV/EBIT Ratio | 33.71 | 44.30 | 27.46 | 51.46 | 9.37 | 64.96 |
EV/FCF Ratio | 63.95 | 134.22 | - | - | 10.55 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.35 | 0.33 | 0.34 | 0.22 | 0.19 | 0.15 |
Debt / EBITDA Ratio | 1.97 | 1.88 | 1.55 | 1.24 | 0.37 | 0.75 |
Debt / FCF Ratio | 9.93 | 14.31 | - | - | 0.47 | - |
Net Debt / Equity Ratio | 0.10 | 0.08 | 0.07 | -0.06 | -0.39 | -0.17 |
Net Debt / EBITDA Ratio | 0.59 | 0.44 | 0.33 | -0.35 | -0.74 | -0.84 |
Net Debt / FCF Ratio | 2.93 | 3.34 | -2.98 | 0.21 | -0.94 | 2.31 |
Asset Turnover | 0.42 | 0.42 | 0.49 | 0.51 | 1.25 | 0.68 |
Inventory Turnover | 1.02 | 1.04 | 1.10 | 1.58 | 4.15 | 1.60 |
Quick Ratio | 1.41 | 1.44 | 1.22 | 1.39 | 1.20 | 1.51 |
Current Ratio | 2.19 | 2.13 | 1.90 | 2.20 | 1.63 | 2.30 |
Return on Equity (ROE) | 2.78% | 2.54% | 10.40% | 11.22% | 51.59% | 17.89% |
Return on Assets (ROA) | 2.60% | 2.72% | 5.11% | 3.92% | 22.55% | 7.61% |
Return on Invested Capital (ROIC) | 4.44% | 4.74% | 11.13% | 10.88% | 72.04% | 17.98% |
Return on Capital Employed (ROCE) | 5.30% | 5.60% | 10.00% | 8.50% | 42.80% | 13.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 0.54% | 0.29% | 3.35% | 2.73% | 9.08% | 1.46% |
FCF Yield | 1.64% | 0.77% | -0.70% | -5.66% | 9.13% | -0.81% |
Dividend Yield | 0.22% | 0.15% | 1.35% | 1.23% | 2.41% | 1.24% |
Payout Ratio | 457.47% | 606.57% | 56.06% | 79.58% | 16.70% | 5.32% |
Buyback Yield / Dilution | -8.61% | -2.56% | 0.64% | -0.70% | -5.53% | -6.03% |
Total Shareholder Return | -8.39% | -2.42% | 1.99% | 0.53% | -3.12% | -4.79% |